Nordic Nanovector's Betalutin receives fast track designation from US FDA for marginal zone lymphoma

Nordic Nanovector

29 June 2020 - Nordic Nanovector today announces that the US FDA has granted fast track designation for investigating Betalutin (177Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior systemic therapies.

Nordic Nanovector is evaluating the opportunity to develop Betalutin as a single-agent treatment for marginal zone lymphoma, a rare type of non-Hodgkin's lymphoma. 

Betalutin has demonstrated a very promising clinical effect in nine marginal zone lymphoma patients in the Phase 1/2a LYMRIT 37-01 trial.

Read Nordic Nanovector press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track